| UHC Surest Medical and Drug | Hearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Intensity-Modulated Radiation Therapy – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Percutaneous Vertebroplasty and Kyphoplasty – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Proton Beam Radiation Therapy – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Radiation Therapy: Fractionation, Image-Guidance, and Special Services – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Ryplazim® (Plasminogen, Human-Tvmh) – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Surgery of the Hip – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Tocilizumab (Actemra®, Tofidence®, & Tyenne®) Injection for Intravenous Infusion - Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Treatment of Temporomandibular Joint Disorders – Commercial and Individual Exchange Medical Policy | 2026-03-01 |